Prosecution Insights
Last updated: October 02, 2026

Examiner: SHIM, DAVID M.

Tech Center 1600 • Art Units: 1621 1626 1629

This examiner grants 58% of resolved cases

Analysis

SHIM, DAVID M. is an examiner in Tech Center 1600 and Art Unit 1621. The data includes 96 resolved cases. The allowance rate is 58.3 percent, which reflects the frequency of grants for applications assigned to this examiner. Practitioners can use the 58.3 percent allowance rate to assess the likelihood of a positive outcome during prosecution. The 96 resolved cases provide a data set for analyzing the examiner's historical patterns in this specific technological area.

The interview lift is 58.3 percent. This metric indicates that the allowance rate is higher when an interview is conducted compared to the baseline rate of 58.3 percent. An interview lift of 58.3 percent suggests that direct communication is an exceptionally effective strategy for overcoming rejections. Practitioners should prioritize scheduling an interview to clarify technical issues or to negotiate claim scope. This 58.3 percent lift shows a clear benefit to verbal engagement with the examiner.

The median days to allowance is 1078. This number represents the middle point of the time required to reach a grant. A median of 1078 days provides a benchmark for the expected duration of the examination process. The combination of the 58.3 percent allowance rate and the 1078-day pendency defines the current prosecution environment for this examiner. These figures help applicants to manage expectations regarding both the timing and the probability of success.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

58.3%
Allow Rate
-1.7% vs TC avg
133
Total Applications
+58.3%
Interview Lift
1078
Avg Prosecution Days
Based on 96 resolved cases, 2023–2026

Rejection Statute Breakdown

0.4%
§101 Eligibility
13.8%
§102 Novelty
37.6%
§103 Obviousness
35.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18735506 FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS Non-Final OA Northwestern University
18721947 AN INJECTABLE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISEASES IN ANIMALS Non-Final OA Intervet Inc.
18845718 NOVEL TAFAMIDIS SYNTHESIS METHOD Non-Final OA KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
18850466 TYK2 INHIBITORS AND USES THEREOF Non-Final OA Takeda Pharmaceutical Company Limited
18646178 COMPOUNDS Non-Final OA GlaxoSmithKline Intellectual Property Development Limited
18853933 EGFR INHIBITORS Non-Final OA Blueprint Medicines Corporation
18696960 PIKFYVE KINASE INHIBITOR Non-Final OA HANMI PHARM. CO., LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month